ENZALUTAMIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (2012)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L02BB04
UNII: 93T0T9GKNU

Structure
InChI Key WXCXUHSOUPDCQV-UHFFFAOYSA-N
Smile CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F
InChI
InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)

Physicochemical Descriptors

Property Name Value
Molecular Formula C21H16F4N4O2S
Molecular Weight 464.44
AlogP 3.99
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 3.0
Polar Surface Area 76.44
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 32.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Androgen Receptor antagonist
Primary Target
Androgen receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Protease Serine protease Serine protease PA clan Serine protease S1A subfamily
- 130 - - -
Enzyme Transferase
- - - - 12.87
Ion channel Ligand-gated ion channel GABA-A receptor
- 3000-4800 - - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 1
- 29000 - 14000 -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 4
49-11390 14-8610 6520-295400 17-3641.29 20-97

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Prostatic Neoplasms 4 D011471 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Neoplasms 4 D009369 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Carcinoma, Hepatocellular 2 D006528 ClinicalTrials
Lymphoma, Mantle-Cell 2 D020522 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Triple Negative Breast Neoplasms 2 D064726 ClinicalTrials
Endometrial Neoplasms 2 D016889 ClinicalTrials
Adenocarcinoma 2 D000230 ClinicalTrials
Uterine Neoplasms 2 D014594 ClinicalTrials
Carcinoma 2 D002277 ClinicalTrials
Liver Diseases 1 D008107 ClinicalTrials
Pancreatic Neoplasms 1 D010190 ClinicalTrials
Kidney Diseases 1 D007674 ClinicalTrials
Carcinoma, Renal Cell 1 D002292 ClinicalTrials

Related Entries

MCS

Scaffolds

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
21.67
Nervous system disorders
11.55
Gastrointestinal disorders
9.37
Musculoskeletal and connective tissue disorders
7.17
Vascular disorders
5.77
Psychiatric disorders
5.39
Injury, poisoning and procedural complications
5.13
Investigations
4.92
Cardiac disorders
4.89
Respiratory, thoracic and mediastinal disorders
4.04
Metabolism and nutrition disorders
3.23
Skin and subcutaneous tissue disorders
3.11
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.87
Infections and infestations
2.31
Renal and urinary disorders
2.15

Cross References

Resources Reference
CAS NUMBER 915087-33-1
ChEBI 68534
ChEMBL CHEMBL1082407
DrugBank DB08899
DrugCentral 4628
FDA SRS 93T0T9GKNU
Guide to Pharmacology 6812
KEGG D10218
PubChem 15951529
SureChEMBL SCHEMBL189749
ZINC ZINC000034806477
CONTENTS